Summa Corp’s Generate Biomedicines GENB Stock Holding History

Summa Corp’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$250K	Buy	+16,666	New	+$256K	0.05%	85

Other funds holding GENB

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return

Dynamic Advisor Solutions Phoenix, Arizona $3.52B AUM 15.33% 1-Year Est. Return

Magnus Financial Group New York $1.5B AUM 16.47% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Pictet Bank & Trust Nassau, Bahamas $85.5M AUM 18.48% 1-Year Est. Return

Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Summa Corp's GENB Position: Q3 2026 in Review

Summa Corp opened a new position in Generate Biomedicines (GENB) in Q3 2026: 16,666 shares worth $250K. The stake represents 0.05% of the portfolio and ranks #85 among its holdings.

18 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

Summa Corp held 16,666 shares of Generate Biomedicines worth $250K as of Q3 2026.
Generate Biomedicines was a new Summa Corp position in Q3 2026.
Generate Biomedicines made up 0.05% of Summa Corp's portfolio in Q3 2026, its #85 holding.
18 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on Summa Corp's 13F filing for Q3 2026, filed 30 Oct 2026.